Download PDF
Onkologische Welt 2011; 02(02): 72-74
DOI: 10.1055/s-0038-1631216
Kongressnachlese AML XIII
Schattauer GmbH

Fortschritte durch intensivierte Chemotherapie und bessere Supportivtherapie: Akute myeloische Leukämie

Angelika Bischoff Dr. med.
Further Information

Publication History

Publication Date:
02 February 2018 (online)

Also available at
    Permissions and Reprints

Die Prognose von Patienten mit einer akuten myeloischen Leukämie (AML) hat sich in den vergangenen drei Dekaden stetig verbessert. Heute erreichen insgesamt 60–70% der Patienten komplette Remissionen mit langdauerndem krankheitsfreien Überleben. Bei 25 bis 40% ist eine Heilung möglich. Dieser Fortschritt beschränkt sich jedoch weitgehend auf Patienten unter 60 Jahren. Möglich wurde er vor allem durch Intensivierung der Chemotherapie und Verbesserung der supportiven Therapie, berichtete Prof. Jan Braess, München, auf dem Symposium Acute Leukemias XIII Ende Februar in München.

 

  • Literatur

  • 1 Büchner T. et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German acute myeloid leukemia cooperative group. J Clin Oncol 2009; 27: 61-69.
    CrossrefPubMedGoogle Scholar
  • 2 Creutzig U. et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM-trials. Leukemia 2005; 19: 2030-2042.
    CrossrefPubMedGoogle Scholar
  • 3 Dufour A. et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010; 28 (04) 570-577.
    CrossrefPubMedGoogle Scholar
  • 4 Gardin C. et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109: 5129-5135.
    CrossrefPubMedGoogle Scholar
  • 5 Green CL. et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010; 28 (16) 2739-2747.
    CrossrefPubMedGoogle Scholar
  • 6 Juliusson G. et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood 2009; 113: 4179-4187.
    CrossrefPubMedGoogle Scholar
  • 7 Krug U. et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukemia: a web-based application for prediction of outcomes. Lancet 2010; 376: 2000-2008.
    CrossrefPubMedGoogle Scholar
  • 8 Thépot S. et al. Azacitidine (AZA) as first line therapy in AML: Results of the French ATU program. Blood 2009; 114: 843 (ASH Annual Meeting).
    Google Scholar